FamiCord Group Expands into the Czech Republic and Slovakia

FamiCord Group is expanding its presence in Central Europe. With the integration of companies in the Czech Republic and Slovakia, the Group strengthens its position on two promising markets, offering families broader access to stem cell banking and therapies.

FamiCord Group is excited to welcome two promising, fast-growing companies to the Group: NCPK – Národní Centrum Pupečníkové Krve in Ostrava (Czech Republic) and RBSK – Rodinná Banka Perinatálnych a Mezenchymálnych Buniek in Bratislava (Slovakia). These specialized cord blood banks may be small in size, but they bring big potential, offering families professional stem cell collection and storage services. All samples are carefully processed in the Ostrava laboratory by a dedicated and passionate team. Under the guidance of an international Board – Zsuzsanna Takács (Hungary), Paweł Zalecki (Poland), and Jan Šťastný (Czech Republic) – these companies are now positioned to grow even faster. By joining FamiCord, they gain access to the Group’s scale and know-how, while continuing to provide high-quality services. The Czech and Slovak markets are ripe for expansion, with plenty of untapped opportunities in sales, marketing, and partnerships with hospitals and clinics.

As Zsuzsanna Takács, Board Member, GM KRIO in Hungary, highlights: “This acquisition is a new chance not only for our Group, but above all for families in the Czech Republic and Slovakia. By combining the local knowledge and FamiCord international expertise, we will be able to provide wider access to stem cell services and therapies to families living in these countries. It is a great step forward for FamiCord in Central Europe.”

In Slovakia, awareness of cord blood banking among expectant parents is high. While penetration was previously very strong, it has declined in recent years for various reasons. This creates an ideal timing for our growth, as we can leverage the broad awareness together with FamiCord’s strong reputation and transparent operations. In the Czech Republic, penetration remains low, and hospital coverage is also limited, meaning that growth will rely more heavily on education and the establishment of strong hospital partnerships. Cooperation with hospitals and medical professionals will be crucial to increasing visibility and accessibility of stem cell banking in both countries.

 A unique advantage is the favorable client contract structure, with nearly 70% of clients choosing annual payment plans, providing stability and trust- adds Paweł Załęcki, Board Member responsible for finance. 

With this acquisition, FamiCord Group is now firmly established in the Czech and Slovak markets. We will actively grow our presence, work closely with hospitals and clinics, and make high-quality stem cell services more widely available for families. This is a clear step forward in bringing the benefits of our expertise and therapies to more people in Central Europe